Fairvalue-Calculator Fairvalue-Calculator
EN DE

Zhejiang Shengda Bio-Pharm Co (603079) Fair Value & Analysis

Healthcare · CN · Market cap 2.5B CNY

Price¥12.52
Fair Value¥6.30
Upside-49.7%
Quality93/100
Evidence: High Range ¥5.43 – ¥7.90

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Zhejiang Shengda Bio-Pharm Co (603079) currently trades at ¥12.52, while our model-based Fair Value estimate is ¥6.30 — implying the stock looks roughly 49.7% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Zhejiang Shengda Bio-Pharm Co (603079) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥6.30 versus a price of ¥12.52 — about −50% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 603079?
Our 21-model fair value for Zhejiang Shengda Bio-Pharm Co is ¥6.30 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥12.52.
What is the quality score of 603079?
Zhejiang Shengda Bio-Pharm Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.